Terns (TERN) Q2 Net Loss Narrows 16%
Terns Pharmaceuticals (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing therapies for chronic myeloid leukemia (CML) and metabolic diseases, released its second quarter results on August 5, 2025. The most notable news was continued progress in its two lead clinical programs—TERN-701, a kinase inhibitor drug for CML, and TERN-601, an oral GLP-1 receptor agonist drug for obesity—while maintaining a robust cash balance. The GAAP net loss per share was $(0.26), slightly better than the expected $(0.29). Compared to Q2 2024, R&D spending increased. Overall, the period was marked by clinical advancement, prudent cash management, and a significant narrowing of its research and development focus.
Source: Analyst estimates for the quarter provided by FactSet.
Terns Pharmaceuticals develops oral drug candidates targeting cancer (specifically CML) and cardiometabolic diseases, advancing multiple therapies through clinical trials but has no products on the market. Its most advanced medicines are TERN-701 for CML—a cancer of the blood—and TERN-601 for obesity. The company operates fully in clinical development, meaning its worth is closely tied to the progress and outcome of these pipeline programs.
Source Fool.com
